<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="hydrodistillation and verified some biological activities on a panel of" exact="hepatocellular carcinoma" post="cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative breast"/>
 <result pre="hepatocellular carcinoma cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative" exact="breast cancer" post="cell lines (SUM 149, MDA-MB-231). In the essential oil"/>
 <result pre="carcinoma cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative breast" exact="cancer" post="cell lines (SUM 149, MDA-MB-231). In the essential oil"/>
 <result pre="and to verify some biological activities on a panel of" exact="hepatocellular carcinoma" post="cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative breast"/>
 <result pre="hepatocellular carcinoma cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative" exact="breast cancer" post="cell lines (SUM 149, MDA-MB-231). Both cancer models are"/>
 <result pre="carcinoma cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative breast" exact="cancer" post="cell lines (SUM 149, MDA-MB-231). Both cancer models are"/>
 <result pre="triple negative breast cancer cell lines (SUM 149, MDA-MB-231). Both" exact="cancer" post="models are highly aggressive with poor prognosis and are"/>
 <result pre="Hepatocellular carcinoma cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative" exact="breast cancer" post="cell lines (SUM 149, MDA-MB-231) were used. The human"/>
 <result pre="carcinoma cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative breast" exact="cancer" post="cell lines (SUM 149, MDA-MB-231) were used. The human"/>
 <result pre="cancer cell lines (SUM 149, MDA-MB-231) were used. The human" exact="hepatocellular carcinoma" post="cell line HA22T/VGH was kindly provided by Professor Massimo"/>
 <result pre="short tandem repeat profiling (BMR Genomics, Padua, Italy). The human" exact="breast cancer" post="cell lines MDA-MB-231 (ATCC ®: HTB-26 ™—Rockville, MD, USA)"/>
 <result pre="tandem repeat profiling (BMR Genomics, Padua, Italy). The human breast" exact="cancer" post="cell lines MDA-MB-231 (ATCC ®: HTB-26 ™—Rockville, MD, USA)"/>
 <result pre="oil by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy methoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) assay on a panel of" exact="hepatocellular carcinoma" post="cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative breast"/>
 <result pre="hepatocellular carcinoma cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative" exact="breast cancer" post="cell lines (SUM 149, MDA-MB-231). As shown in Fig"/>
 <result pre="carcinoma cell lines (HA22T/VGH, HepG2, Hep3B) and triple negative breast" exact="cancer" post="cell lines (SUM 149, MDA-MB-231). As shown in Fig"/>
 <result pre="Fig 1 Cytotoxic activity of G. rosmarinifolia essential oil on" exact="cancer" post="cell lines. Cell viability was assessed by MTS. Data"/>
 <result pre="oil induces a strong suppressive growth effects in all tested" exact="cancer" post="cell lines, probably through an increase in free radical"/>
 <result pre="the diterpenes and this hydroxy-methyl-naphthoquinone are NF-κB inhibitors in these" exact="cancer" post="models and to evaluate their possible use as anticancer"/>
 <result pre="or in combination with cisplatin or doxorubicin, on human hepatic" exact="cancer" post="cells. Analysis of their possible relationship to changes in"/>
 <result pre="al. Curcumin as a possible lead compound against hormone-independent, multidrug-resistant" exact="breast cancer" post=". Ann NY Acad Sci. 2009; 1155: 278– 283."/>
 <result pre="Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast" exact="cancer" post=". Ann NY Acad Sci. 2009; 1155: 278– 283."/>
</results>
